循环肿瘤DNA
医学
微小残留病
正电子发射断层摄影术
循环肿瘤细胞
肿瘤科
淋巴瘤
疾病
癌症研究
内科学
癌症
免疫学
病理
抗体疗法
放射科
癌症治疗
液体活检
计算机断层摄影术
化疗
全身疗法
靶向治疗
残余物
DNA
作者
Reid W. Merryman,Mark J. Roschewski
出处
期刊:Blood
[Elsevier BV]
日期:2026-11-10
标识
DOI:10.1182/blood.2026033073
摘要
Response assessment after frontline therapy for large B-cell lymphoma risk-stratifies patients into those at low risk for relapse and those with residual disease. Positron emission tomography scans form the cornerstone of the response criteria but cannot detect molecular-only disease. Circulating tumor DNA detects measurable residual disease (MRD) after therapy which is emerging as an adjunct tool for complex clinical decision-making. We discuss how MRD after therapy can be clinically implemented and additional data needed to unlock its full potential.
科研通智能强力驱动
Strongly Powered by AbleSci AI